Promoting a research agenda for cancer treatment for intravenous devices with clinicians in Europe; the PRACTICE survey

IF 2 Q3 HEALTH POLICY & SERVICES

Journal of Cancer Policy Pub Date : 2025-09-22 DOI:10.1016/j.jcpo.2025.100643

Caitriona Duggan , Orlaith Hernon , Andrew J. Simpkin , Viktor Manasek , Julio C. de la Torre-Montero , Paulo Santos-Costa , Jonathan G. Moss , Christina H. Ruhlmann , Knut Taxbro , Miguel Angel Rodriguez- Calero , Rodrigo Oom , Rita Barroca , Onagh O. Grady , Jacqueline Daly , Ian Blanco-Mavillard , Nikolina Dodlek , Jiri Charvát , Saloa Unanue-Arza , Bibiana Krakovska , Peter J. Carr

{"title":"Promoting a research agenda for cancer treatment for intravenous devices with clinicians in Europe; the PRACTICE survey","authors":"Caitriona Duggan , Orlaith Hernon , Andrew J. Simpkin , Viktor Manasek , Julio C. de la Torre-Montero , Paulo Santos-Costa , Jonathan G. Moss , Christina H. Ruhlmann , Knut Taxbro , Miguel Angel Rodriguez- Calero , Rodrigo Oom , Rita Barroca , Onagh O. Grady , Jacqueline Daly , Ian Blanco-Mavillard , Nikolina Dodlek , Jiri Charvát , Saloa Unanue-Arza , Bibiana Krakovska , Peter J. Carr","doi":"10.1016/j.jcpo.2025.100643","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>The <em>PRACTICE</em> survey aimed to characterize vascular access device (VAD) practices for systemic anti-cancer therapy (SACT) across Europe, addressing gaps in clinician decision-making, training, and complication management.</div></div><div><h3>Methods</h3><div>Conducted as a cross-sectional survey from May to October 2024, the study engaged healthcare professionals (HCPs) from 18 European countries, with 403 completing demographic questions and 166 responding to procedural and training-related queries.</div></div><div><h3>Results</h3><div>Results revealed significant variability in VAD selection, influenced by institutional protocols, geographic location, and the presence of vascular access teams (VATs). Oncologists were identified as primary decision-makers (36 %), though nursing staff played a pivotal role in daily management. Peripheral intravenous catheters (PIVCs) dominated in Ireland and Finland (43–49 %), while tunnelled implantable devices (TIVADs) were preferred in Belgium (65 %). Barriers to optimal VAD selection included insufficient training (80 % sought further education) and inconsistent guideline adoption (51 % reported institutional protocols).</div></div><div><h3>Conclusion</h3><div>The study underscores the need for standardised practices, interdisciplinary collaboration, and enhanced training. Findings highlight opportunities for integrating VAD selection into cancer care certification metrics and fostering partnerships between oncology and vascular access societies.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"46 ","pages":"Article 100643"},"PeriodicalIF":2.0000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000876","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The PRACTICE survey aimed to characterize vascular access device (VAD) practices for systemic anti-cancer therapy (SACT) across Europe, addressing gaps in clinician decision-making, training, and complication management.

Methods

Conducted as a cross-sectional survey from May to October 2024, the study engaged healthcare professionals (HCPs) from 18 European countries, with 403 completing demographic questions and 166 responding to procedural and training-related queries.

Results

Results revealed significant variability in VAD selection, influenced by institutional protocols, geographic location, and the presence of vascular access teams (VATs). Oncologists were identified as primary decision-makers (36 %), though nursing staff played a pivotal role in daily management. Peripheral intravenous catheters (PIVCs) dominated in Ireland and Finland (43–49 %), while tunnelled implantable devices (TIVADs) were preferred in Belgium (65 %). Barriers to optimal VAD selection included insufficient training (80 % sought further education) and inconsistent guideline adoption (51 % reported institutional protocols).

Conclusion

The study underscores the need for standardised practices, interdisciplinary collaboration, and enhanced training. Findings highlight opportunities for integrating VAD selection into cancer care certification metrics and fostering partnerships between oncology and vascular access societies.

查看原文本刊更多论文

与欧洲临床医生一起推动静脉注射装置治疗癌症的研究议程；PRACTICE调查。

目的：PRACTICE调查旨在描述整个欧洲用于全身抗癌治疗（SACT）的血管通路装置（VAD）实践，解决临床医生决策、培训和并发症管理方面的差距。方法：采用横断面调查的方法，于2024年5月至10月对来自18个欧洲国家的卫生保健专业人员（HCPs）进行了研究，其中403人完成了人口统计问题，166人回答了程序和培训相关问题。结果：结果显示，VAD的选择存在显著差异，受机构协议、地理位置和血管通路小组（VATs）存在的影响。肿瘤学家被确定为主要决策者（36%），尽管护理人员在日常管理中发挥了关键作用。外周静脉导管（pivc）在爱尔兰和芬兰占主导地位（43-49%），而隧道植入装置（tivad）在比利时更受欢迎（65%）。选择最佳VAD的障碍包括培训不足（80%的人寻求继续教育）和指南采用不一致（51%的人报告了机构协议）。结论：该研究强调了标准化实践、跨学科合作和加强培训的必要性。研究结果强调了将VAD选择纳入癌症护理认证指标以及促进肿瘤和血管准入协会之间合作的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊